Type 2 diabetes mellitus (T2DM) and non-alcoholic fatty liver disease (NAFLD) are characterised by high GCG levels and GCG resistance [5,6]; manipulation of GCG signalling is a potential pharmacological strategy for the treatment of these conditions [7,8]. This evidence concerns the gene GCG and metabolic dysfunction-associated steatotic liver disease.